About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) ...

Non-alcoholic fatty liver disease has no early signs. Is your liver at risk? Expert reveals these simple tests could save ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

At the moment, Madrigal Pharmaceuticals seems to be in the lead to bring a NASH drug to market, after its daily oral drug resmetirom met primary and secondary objectives in a phase 3 NAFLD trial ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...

It encompasses a spectrum of diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH) and can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. The global ...

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...

Hepatic fat accumulation can progress from simple NAFLD to non-alcoholic steatohepatitis (NASH) which includes hepatocellular injury, inflammation, and fibrosis. In more severe cases, complications ...

The MAESTRO-NASH OUTCOMES trial will further assess resmetirom's efficacy and safety. At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...